Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goals of this clinical study are to learn more about the study drug, GS-0272, and its
safety and tolerability following multiple doses in participants with rheumatoid arthritis
(RA) and systemic lupus erythematosus (SLE).
The primary objectives of this study are to assess the safety and tolerability of multiple
ascending subcutaneous (SC) doses of GS-0272 and to characterize the pharmacokinetics of
GS-0272 following multiple SC doses of GS-0272, in participants with RA or SLE.